Across TCGA pan-cancer cohorts, MAGEB6B RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MAGEB6B’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MAGEB6B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAGEB6B is over-expressed in tumor.
LIHC and LUSC are the cancer types where MAGEB6B tumor–normal differential expression is most reproducible.